ADALTA LIMITED — Call Transcript 2018

Jul 25, 2018

ASX Announcement

AdAlta investor conference call and Q+A session

MELBOURNE Australia, 26th July 2018 , AdAlta Limited (ASX: 1AD), the biotechnology company advancing its lead i-body candidate towards clinical development, is pleased to invite shareholders to participate in an investor conference call on Wednesday, 1 August, 2018.

During the call, CEO Sam Cobb will provide an update on the progress AdAlta's lead therapeutic program for the treatment of Idiopathic Pulmonary Fibrosis, AD-214; discuss the Company's recent Placement to institutional and sophisticated investors and will conduct a Q+A session, covering any questions on the Share Purchase Plan Offer, which is currently open to shareholders.

Call details

Date and time:

Wednesday, 1 August at 11 am AEST.

Dial in details:

Participant toll: +61 2 8038 5221 Participant toll-free: 1800 123 296

Conference ID: 5687897

The session will be recorded and a copy will be made available via the company's website.

-ENDS-

Notes to Editors

About AdAlta

AdAlta Limited is an Australian based drug development company headquartered in Melbourne. The Company is focused on using its proprietary technology platform to generate i-bodies, a new class of protein therapeutics, with applications as therapeutic drugs to treat disease.

I-bodies are a promising, novel class of drugs that offer a new and more effective approach to treating a wide range of human diseases. They are identified and developed using our proprietary technology platform.

We have pioneered a technology that mimics the shape and stability of a crucial antigenbinding domain, that was discovered initially in sharks and then developed as a human protein. The result is a range of unique compounds, now known as i-bodies, for use in treating serious diseases.

AdAlta is developing its lead i-body candidate, AD-214, for the treatment of idiopathic pulmonary fibrosis (IPF) and other human fibrotic diseases, for which current therapies are sub-optimal and there is a high-unmet medical need.

The Company also plans to continue further drug discovery and development directed towards other drug targets and diseases with its i-body technology platform.

Further information can be found at: www.adalta.com.au.

For more information, please contact: AdAlta Limited

Sam Cobb, CEO Tel: +61 (0)3 9479 5159 E: s.cobb@adalta.com.au